OBJECTIVE
To evaluate the incidence, risk factors, and clinical outcomes associated with venous thromboembolism (VTE) in patients with gynecologic cancer treated with immune checkpoint inhibitors (ICI).
METHODS
This retrospective cohort study included patients with gynecologic malignancies treated with ICI at a singl...
Cassidy Abdeen, Jessica Sciuva, Reed M. O'Connor et al.· Gynecologic Oncology· 0 citations
The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biomarkers and clinical outcomes were assessed.
Andrew B. Nixon, Danielle M. Enserro, David P. Bender et al.· Cancer· 0 citations
OBJECTIVE
To assess gynecologic oncology professionals' perspectives on biomarker testing and molecularly informed treatment for endometrial cancer across Latin America and to identify barriers to precision care adoption.
METHODS
This was a secondary analysis of a multi-national, cross-sectional, web-based Internatio...
F. Noll, G. Dal Molin, F. Backes et al.· International Journal of Gyn...· 0 citations
OBJECTIVES
Clinical trials are essential to therapeutic advancement, yet access to trials in ovarian cancer may not be equitably distributed. This study evaluated associations between community-level social vulnerability and county-level availability of interventional ovarian cancer clinical trials in the United States...
Reed M. O'Connor, Jennifer A. Sinnott, Caitlin E. Meade et al.· Gynecologic Oncology· 0 citations
It is demonstrated that TLS, particularly Polη-dependent bypass, is a critical mechanism enabling replication fork rescue and survival under PARPi therapy, and targeting TLS provides a promising therapeutic strategy to augment PARPi efficacy and prevent resistance in BRCA-deficient ovarian cancer.
Na Li, Kousalya Lavudi, Qian-Yun Ge et al.· Cancer Research· 0 citations
It is suggested that digital inequities may contribute to site- and age-specific disparities in gynecologic cancer survival, underscoring the need to address barriers to digital access as part of efforts to improve cancer outcomes.
Julia Chalif, Laura M. Chambers, Caitlin E. Meade et al.· International Journal of Gyn...· 0 citations
In this cohort of CC patients treated with IO, approximately 39% and 55% of patients were categorized as high risk according to pre-treatment NRI and PNI, respectively, and high-risk PNI and NRI classifications were associated with differences in irAEs, IO response, and oncologic outcomes.
Julia Chalif, Molly A. Morton, Eric M. McLaughlin et al.· Gynecologic Oncology Reports· 0 citations
Delayed diagnosis of vulvar SCC was associated primarily with provider and healthcare system-related factors rather than patient or tumor characteristics, which may help facilitate more prompt diagnosis and therapeutic intervention.
Julia C. Sakach, Molly A. Morton, Jessica Velasquez et al.· Gynecologic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.